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One of the main indications for stereotactic surgery in Parkinson’s disease (PD) is the
control of levodopa-induced dyskinesia. This can be achieved by pallidotomy and globus
pallidus internus (GPi) deep brain stimulation (DBS) or by subthalamotomy and subthala-
mic nucleus (STN) DBS, which usually allow for a cut down in the dosage of levodopa. DBS
has assumed a pivotal role in stereotactic surgical treatment of PD and, in fact, ablative
procedures are currently considered surrogates, particularly when bilateral procedures are
required, as DBS does not produce a brain lesion and the stimulator can be programed to
induce better therapeutic effects while minimizing adverse effects. Interventions in either
the STN and the GPi seem to be similar in controlling most of the other motor aspects
of PD, nonetheless, GPi surgery seems to induce a more particular and direct effect on
dyskinesia, while the anti-dyskinetic effect of STN interventions is mostly dependent on a
reduction of dopaminergic drug dosages. Hence, the si ne qua non-condition for a reduction
of dyskinesia when STN interventions are intended is their ability to allow for a reduction of
levodopa dosage. Pallidal surgery is indicated when dyskinesia is a dose-limiting factor for
maintaining or introducing higher adequate levels of dopaminergic therapy. Also medica-
tions used for the treatment of PD may be useful for the improvement of several non-motor
aspects of the disease, including sleep, psychiatric, and cognitive domains, therefore, dose
reduction of medication withdrawal are not always a fruitful objective.
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INTRODUCTION
Treatment of levodopa-induced dyskinesia (LID) is one of the
most common indications for stereotactic surgery in Parkinson’s
disease (PD). Control of LID can be accomplished by providing
significant relief on the motor symptoms of PD through medica-
tion optimization, typically through subthalamic nucleus (STN)
deep brain stimulation (DBS), or by pallidotomy or globus pal-
lidus internus (GPi) DBS, which are thought to have a direct effect
on dyskinesia (1). Currently, DBS has become the preferred stereo-
tactic procedure in PD, however, ablative surgery continues to be
performed and can be quite effective especially when dyskinesia are
significantly more prominent on one body side. In this review, we
will address both forms of surgical techniques, their indications,
differentials, and outcomes.
ABLATIVE SURGERY
The indication for any form of stereotactic ablative surgery has
always been the symptomatic treatment of certain motor features
of PD as identified during a detailed multi-disciplinary workup.
As early as the 50s, the inner segment of the GPi and the ansa
lenticularis has been the common choice for functional neurosur-
geons (2). This approach was advocated and further reinforced
following the observation that ligation of the anterior choroidal
artery, performed for the treatment of accidental bleeding in a
PD patient, resulted in relief of tremor (3, 4). As this technique
(ansa – pallidotomy) became more widely utilized, the results for
tremor control were mixed, despite the good outcome for rigidity.
As a result, pallidotomy was gradually replaced by thalamotomy,
which exerted a more optimal tremor control (5). The failure to
reduce tremor in some cases was likely due to a failure to target
the appropriate postero-ventral pallidum, which was a limitation
of early technology. However, with the advent of levodopa in the
1960s, stereotactic surgery became gradually less popular and did
not re-emerge again until the early 90s (6).
The renaissance of stereotactic surgery for patients with PD
was galvanized by the weaknesses of levodopa therapy that were
gradually surfacing (7). The first disappointment was the evidence
that it does not interfere positively with disease progression, as it is
now well appreciated after decades of use. Additionally, due to the
high doses sometimes required to improve tremor, motor fluctu-
ations, and LID started to be noticed. As most clinicians continue
to witness today, medical pharmacological management of PD is
challenging with the continuous attempt to balance the relief of
parkinsonian motor signs against motor fluctuations and induc-
tion of dyskinesia, often with neither being managed adequately
(8). The setback related to levodopa was allied with advancements
from physiological and surgical aspects, and also by the more accu-
rate understanding of the organization of the basal ganglia (BG),
better surgical techniques, and the use of neuroimaging for more
precise target localization. At that time, thalamotomy was revived,
and, in addition to improvements in the motor aspects of PD,
several authors reported drastic suppression of LID (9).
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Svennilson et al. reported that when the postero-ventral GPi
was lesioned additional benefit to general motor function (inter-
preted as corresponding to relief of akinesia) could be obtained
(10). Later, Laitinen et al. returned to the initial target and
the postero-ventral GPi became the preferred surgical treatment
for PD patients. In the classical report from 1992, Laitinen’s
group showed favorable outcomes that included not only robust
improvements in the cardinal signs of PD, but also significant
amelioration of LID (11).
At approximately the same time, anatomic and physiological
studies confirmed that the GPi and STN were both overactive in
PD. Also, experimental studies demonstrated that lesions in these
structures could improve parkinsonism and dyskinesia in animal
models (12–14), although the classical BG model predicted that
pallidotomy would worsen dyskinesia. This discrepancy between
theoretical and practical outcomes is probably the result of inter-
ference with abnormal firing patterns (rather than rates) in circuit
neurons (15).
Both the clinical report by Laitinen et al. and the pathophysi-
ological laboratory-based developments in PD reinforced the role
of pallidotomy for treatment of LID in PD.
PALLIDOTOMY
During the second half of the 90s, many studies reported that uni-
lateral pallidotomy in patients with PD provided successful control
of contralateral dyskinesia. At that time, Lozano et al. (15) pub-
lished the results of pallidotomy in 14 patients with rigid akinetic
PD, complicated by severe LID, motor fluctuations, but with intact
cognition. Motor improvements in the OFF medication condition
were mainly contralateral. The most dramatic improvement was
for ON period LID, which were shown to be reduced by 92% in the
contralateral side after 6 months. The typical complications of this
procedure, homonymous hemianopia, facial paresis, and hemi-
paresis, were not observed, except for mild and transient facial
droop in three cases (noted by clinicians but not the patients).
Two years later, the same group published a series of 40 cases,
some with a longer follow-up: 27 for 1 year and 11 for 2 years.
Short term results were similar to their previous study, however
trend analysis revealed a slight worsening of contralateral dyskine-
sia after the first year, and a loss of benefit for ipsilateral dyskinesia
by the second year. Age had an impact on OFF period motor
signs, with those older than 65 retaining less improvement after
6 months. LID responded similarly in the two age groups studied.
There were no significant reductions in dopaminergic therapy after
surgery. Persistent adverse events included facial weakness (two
cases), bulbar deficits (three cases), mild dementia (three cases),
and worsening of handwriting in four cases (16). The findings in
the same cohort were also described after a much longer follow-
up (mean 52 months), showing a sustained improvement in OFF
period contralateral motor signs and in LID. Other than dyskinesia
and levodopa responsive motor signs, no additional characteristics
had a significant impact on long-term surgical outcome (17).
In 1998, another group published a preliminary study with a
series of 26 PD patients, confirming that the most significant effect
following unilateral ventral medial pallidotomy was the reduction
of contralateral LID by 67%, while ipsilateral and axial dyskinesia
also improved (both around 50%) significantly. The improvement
in underlying parkinsonism as measured by comparing the Uni-
fied Parkinson’s Disease Rating Scale (UPDRS) scores in the OFF
state before and 3 months after surgery, was less robust (27%).
On medication, no significant post-operative improvements in
parkinsonism were detected and antiparkinsonian medication
dosages increased by 11% post-operatively. The presence of dis-
abling LID, therefore, was considered the major indication for this
surgical procedure. Two (7.7%) patients died due to cerebral hem-
orrhages directly related to surgery, while another 15% had major
complications (significant focal motor and bulbar deficits) (18).
In 2003, the first randomized, prospective controlled trial com-
paring pallidotomy with best medical therapy was published. The
study included 18 patients in each group, showing, after 6 months,
a 32% improvement of the total UPDRS motor score in the sur-
gical group versus only a 5% deterioration for those randomized
for medical therapy. Mean score improvement in the dyskinesia
section of the UPDRS (Part IV) for the surgical group was 45%,
whereas patients kept on medical therapy worsened by 8%. The
study also revealed that LID improved after pallidotomy in all
patients, and two-thirds had “complete relief” on the contralat-
eral side. Also, there was a 36% reduction in ipsilateral dyskinesia
severity. Levodopa equivalent doses remained unchanged. There
were no fatal outcomes and complications occurred in three cases
(16.7%). This study also showed that the age had a clear rela-
tionship with clinical outcome, independent of disease duration,
with younger patients showing more improvement. This effect was
continuous, with no apparent threshold (19).
The series with the longest follow-up was by Kleiner-Fisman
et al. and included 10 patients, showing a trend toward signifi-
cance lasting up to 12 years in contralateral LID (20), and by Hariz
and Bergenheim who reviewed 13 of the 38 patients described in
Laitinen’s original study from 1992. Mean follow-up was 10.5 years
(up to 13.5), and the effect of surgery remained consistent for con-
tralateral LID, but varied for the appendicular OFF period signs.
The authors went as far as to consider pallidotomy as a prophylactic
measure against LID (21).
Lesion size does not seem to have a significant effect on response
(22), however, the optimal location within the GPi that improved
dyskinesia is a matter of controversy. Lesion location and size
may be different from that required to ameliorate other PD signs,
and some experts still advocate a bigger lesion size for prolonged
benefit. While anteromedially placed lesions seems to be better
correlated with improvement in contralateral LID,central and pos-
terolateral placed lesions improved OFF parkinsonian signs (23).
However, lesions placed in more ventral locations or anywhere in
the postero-ventral GPi have been shown to be equally effective
(16). Differences in outcome measures as well as in methods of
determining lesion location probably account for many of these
discrepancies.
Bilateral pallidotomies, staged and simultaneous, produce sim-
ilar improvements in OFF motor and ON dyskinesia to unilat-
eral procedures, with the possible advantage of improvements in
axial dyskinesia, dystonia, and, arguably, selected aspects of gait
such as walking speed and freezing (24, 25). These good results
were undermined by unacceptable cognitive and bulbar (mainly
speech) adverse effects (26). Only a few other studies have shown
different perspectives (27, 28). The series by Parkin et al. (29)
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Table 1 | Patient selection and point to be considered when indicating stereotactic surgery for dyskinesias in Parkinson’s disease.
Advantages Disadvantages Patient profile Post-operative details
Unilateral
pallidotomy
Efficacious Permanent lesion Unable to travel Ipsilateral dyskinesias may
not improve significantly,
requiring continuing
anti-dyskinetic medical
treatment or contralateral
GPi DBS
Less costly than DBS Not reversible Live where DBS is too expensive or
not available
Prefer not to have chronic hardware
Does not require post-operative
programming
Bilateral surgery has higher risk
of side effects
No complications related to
hardware (infections, malfunction)
Does not allow adjustments to
control side effects
High infection risk
GPi DBS Direct improvement in
dyskinesias
Allows adjustments in drug
regimen
May allow for maintaining or
introducing higher levels of
dopaminergic therapy
Synergistic effect with l-DOPA on
axial and other symptoms
No significant change in drug
regimen in many but not all
cases
Ventral and dorsal stimulation
may induce opposite effects on
cardinal motor signs of PD
however this has not been
replicable on all cases
Needs prompt improvement of
severe dyskinesias
Ensure that the beneficial
effect of l-DOPA is not
antagonized by stimulationResponds to low dose l-DOPA, but
has low threshold for dyskinesias
Has l-DOPA responsive non-motor
signs
In the right context, may be safer
for patients with mild pre-existing
cognitive symptoms
STN DBS Allows significant reduction in
dopaminergic drug dosages
Effective for OFF period dystonia
Improvements in dyskinesias
depend on reduction of levodopa
May have negative impact on
cognition
Has severe motor fluctuations
Uses higher doses of l-DOPA
Experiences disabling side effect of
dopaminergic treatment
Intact cognition
Stimulation induced
dyskinesias may appear
after a latency of several
hours if l-DOPA not adjusted
The electrode that induces
dyskinesias is usually the
most effective
More laborious post-operative
management
May worsen or not improve
dyskinesia in brittle dyskinetics
for instance, showed the results in 115 patients who underwent
pallidotomy, 53 of which consisted of bilateral procedures. These
authors reported significant effectiveness for bilateral pallidotomy,
especially for dyskinesia for up to 12 months, at the expense of
worsening of speech in 8% and salivation in 13%, figures that
were similar to those found for unilateral surgery. Table 1 shows
a summary of the advantages, disadvantages, and other aspects to
be considered when a pallidotomy is indicated.
STUDIES COMPARING PALLIDOTOMY AND DEEP BRAIN STIMULATION
OF THE GPi OR STN
Few studies have compared the efficacy and safety of pallidotomy
and DBS of the GPi or STN. Table 2 shows the results of the most
important clinical parameters described in studies of pallidotomy
and DBS techniques. An early, non-randomized trial comparing
results of pallidotomy, STN, and GPi DBS concluded that GPi
DBS had effects similar effects to pallidotomy, but is safer when
bilateral procedures are required. Also, bilateral STN DBS may
improve OFF period motor symptoms to a greater proportion than
the other procedures, and might also improve ON period motor
function (30). In 2004, Esselink et al. (31) compared, in a random-
ized, observer-blind trial, the effect of unilateral pallidotomy and
bilateral STN DBS in patients with PD followed up for 6 months,
confirming that stimulation was more effective in reducing OFF
period motor signs. In addition, this procedure provided better
ON period motor scores and a greater reduction of dopaminergic
drug treatment dosages. Both improved LID and functional scales
equally, and the number of adverse events was similar in both
Table 2 | Effects of unilateral pallidotomy, bilateral GPi and STN deep
brain stimulation (DBS) on general motor improvement (UPDRS III),
dyskinesias (UPDRS IV) and levodopa equivalent daily dose (LEDD).
Motor
improvement (%)
Improvement for
dyskinesias (%)
Reduction
in LEDD
Unilateral
pallidotomy
25–45 45–86 n.s. (0–10%)
GPi DBS 26–43 47–88 n.s. (15–17%)
STN DBS 25–54 20–83 31–47%
Mean improvement after a minimum of 6 months compared to preoperative base-
line. Scores reflect the medication off condition; for DBS, stimulation on. n.s.,
non-significant (17, 32–41).
groups. The same group also published the results after 4 years
with similar findings, except for dopaminergic treatment dosage,
which did not significantly differ between groups after the first
12 months (32).
DEEP BRAIN STIMULATION
After DBS was introduced as a treatment option for movement
disorders in general, this technique has slowly taken over a pivotal
central role in stereotactic surgery. As a matter of fact, ablative
procedures are currently regarded as alternatives, only used when
DBS is not viable due to technical, travel, patient preference, and
economic reasons (42, 43).
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Two of the reasons that favor DBS, particularly if bilateral pro-
cedures are required, are the facts that it is not intended to produce
a brain lesion, and that the stimulator can be programed with
respect to several variables, including electrode location, ampli-
tude, frequency, and pulse width, to induce better therapeutic
effects while minimizing adverse effects. In the case of PD, DBS
electrodes have been placed in two main BG targets: the GPi, and
the STN, though other targets are also possible (44).
GPi DBS
The first study to report results of this procedure described three
patients in 1994, with the post-operative results described as
“excellent,” reflecting improvements in all motor signs of the dis-
ease, as well as for motor fluctuations and LID (45). During the
following decade, descriptions of larger series confirmed these
findings. A study with a follow-up of at least 24 months showed
that the mean improvements in the UPDRS motor and activities
of daily living scores after 12 months were more than 50%, motor
fluctuations were reduced from 40 to 10%, and the score for LID
was reduced to one third. Doses of levodopa tended to remain
unchanged. Half of the patients experienced a slight worsening
of levodopa and stimulation resistant gait and bulbar symptoms
following 12 months (46). In 2000, a study by Kumar et al. (34)
showed the results seen on a cohort of 22 consecutive cases of
PD treated with GPi DBS, 17 of whom had bilateral surgeries.
Post-operatively, at 6 months, the motor improvement in the OFF
condition reached 31 and 66% reduction in LID.
The first double-blind, crossover study evaluating the results of
GPi and STN DBS in PD was performed in 2001, showing that both
procedures induced significant improvements in motor function
and dyskinesia (by 58% for STN and 66% for GPi DBS), however,
the average medication used, measured in levodopa equivalents,
decreased significantly more for the STN DBS patients (35). A
study with longer follow-up, mean 48.5 months, showed a 64%
mean improvement in dyskinesia after this period (36). Finally,
another study followed up 11 patients with PD who underwent GPi
DBS for up to 5 years, showing that, despite a decline on the motor
benefit for the OFF period scores after 3 years, the improvement
in LID was sustained for up to 5 years (47).
STN DBS
STN DBS for advanced PD was first introduced in the 1990s and is
currently the most common form of a surgical treatment applied
for this disorder worldwide. The initial series reported significant
improvements in OFF period tremor, rigidity, and bradykinesia, as
well as attenuation of motor fluctuations and LID, associated with
a 50% reduction in dopaminergic treatment dosages (48). Sub-
sequent studies confirmed these findings. In 2001, a prospective
study of 91 patients showed, after 6 months, a robust improve-
ment in all motor signs in the OFF condition, in the percentage
of time with good mobility and no dyskinesia, mean dyskinesia
score, as well as a mean reduction in daily levodopa dose equiva-
lents (approximately 60%) (35). At this point, it became clear that
the reduction in dyskinesia could be attributed at least in part to the
reduction of levodopa dosage. However, a few studies showed that
this may not be the only element in this beneficial effect. A study
designed to assess the effect of STN DBS on OFF period dystonia,
and on diphasic and peak dose dyskinesia after a levodopa chal-
lenge using the same suprathreshold dose as before surgery with
the stimulation on, showed a reduction of OFF period dystonia by
90%, and of diphasic dyskinesia by 50%, and of peak dose dysk-
inesia by 30% (49). The same authors had already reported that
chronic STN DBS per se tends to reduce dyskinesia, as opposed
to chronic activation of the dopaminergic system with levodopa.
The authors speculated that this difference may have been due to
the pulsatile nature of levodopa stimulation versus the more con-
tinuous activation provided by chronic STN DBS (50). There was
also an important study by Oyama et al. that elegantly showed
that dyskinesia could possibly be reduced in both the STN and
GPi target. The authors accounted for medication reduction, and
showed that in both targets there was a possibility of dyskinesia
suppression without medication reduction (51).
Long-term studies of bilateral STN DBS in patients with
advanced PD have demonstrated the stability of this therapy over
time. A 5-year prospective study of 49 consecutive patients treated
with STN DBS noted that OFF medication motor scores at 5 years
were still 54% better than baseline (37). Worsening of ON med-
ication akinesia, speech, postural stability, and freezing of gait
was interpreted to be consistent with the natural progression of
PD. However, LID benefits persisted, with dyskinesia disability
and duration at 5 years being improved by 58 and 71%, respec-
tively in comparison with baseline. Similar benefits with respect to
dyskinesia were observed in 37 patients followed for 5 years after
DBS surgery (52). Finally, a comprehensive meta-analysis of 921
patients who underwent STN DBS between 1993 and 2004 noted
an average reduction in LID of 69.1% (53).
MECHANISMS OF ACTION IN REDUCING LEVODOPA-INDUCED
DYSKINESIA
Pallidal stimulation
Restoration of the thalamocortical activity by suppression of the
inhibitory output from the pallidum to the ventrolateral thalamus
is the suspected mechanism for motor improvement underpinning
GPi DBS, however, the cellular mechanisms of high-frequency
stimulation are still unknown. The mechanism of GPi DBS in
reducing dyskinesia is also not completely understood. The cur-
rent views of the BG physiology suggest that inhibition of ventral
GPi activity should induce dyskinesia, however, lesioning of the
ventral pallidum provides relief of dyskinesia (54). One of the
possible justifications for this apparent paradoxical response is
that LID may be more correlated with an abnormal pattern than
with the direction and intensity of the neuronal activity within
the GPi (54, 55). Surgical modification of this patterned activity
might be accomplished by lesioning (direct neuronal inhibition)
or with DBS (indirect inhibition through activation of inhibitory
axons close to the electrode). Dyskinesia might also arise from an
abnormal balance of activity within different functional zones of
the nucleus (ventral versus dorsal GPi) and stimulation may sup-
press this abnormal activity (56, 57). Finally, the anti-dyskinetic
effect of GPi DBS maybe mediated through effects on the sub-
thalamopallidal tract, which projects to the dorsal GP externus
and GPi. Dorsal GPi stimulation might inhibit this projection
and would be expected to improve PD symptoms and induce
dyskinesia (58).
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STN stimulation
STN DBS mimics the effects of levodopa on parkinsonian motor
symptoms and allows reduction of dopaminergic medication,
secondarily relieving dyskinesia as medications are reduced or
withdrawn post-operatively (51). However, improvement of dysk-
inesia is also sometimes observed in the early post-operative period
after implantation of electrodes in the STN, even in the absence
of a reduction of medications (1). This indicates a direct anti-
dyskinetic effect of manipulation of the STN (or the vicinity of
its dorsal border and perhaps the zona incerta), but long-term
relief of dyskinesia generally requires reduction of medications.
The specific site of action in stimulation of the STN is unknown.
Some data indicate that the best effect can be achieved at the lowest
intensity not through stimulation of neurons within the STN, but
by stimulation of tissue dorsal to it, which might affect the palli-
dothalamic bundle, the pallidosubthalamic tract, and/or the zona
incerta (59). Other data indicate that the most effective contact
location appears to be within the anterodorsal portion of the STN,
although current could spread from this location into the directly
superior fields of Forel and zona incerta (60). The observation
that an active DBS contact dorsal to the STN may provide better
control of dyskinesia (indicative of a direct anti-dyskinetic effect)
supports the notion that activation of structures dorsal to the STN
is important in providing relief of parkinsonian symptoms by DBS
of the STN (38). Overall, the specific mechanisms of action of GPi
and STN DBS in suppressing dyskinesia are unknown.
STUDIES COMPARING THE EFFECT OF GPi AND STN DBS
A few studies have compared the effect of GPi and STN DBS on
PD. Table 2 shows the results of the most important clinical para-
meters described in studies comparing these two techniques. The
first study to do that was published in 2001, it had a relatively
short follow-up period after surgery (3 months), and revealed
similar improvements in OFF period motor parameters, as well
as for ON dyskinesia, with the caveat that only the STN group
was able to significantly reduce the levodopa equivalent dose
(35). In 2005, a non-randomized extension of this study with 105
patients followed up for at least 3 years, showed that, in addition
to improvements in all motor signs of parkinsonism in the OFF
condition, STN DBS significantly improved OFF dystonia and ON
dyskinesia, while GPi had a similar effect on ON dyskinesia with
no significant improvement on OFF dystonia. In this study, reduc-
tion in post-operative levodopa equivalent doses was significant
only for the STN group, in which more than 10% of patients
stopped taking levodopa. These changes were sustained after up
to 4 years of follow-up (36). Moro et al., in an double-blind, non-
randomized study with 35 patients who underwent STN DBS and
16 who underwent GPi DBS, found that both procedures induced
significant improvements in OFF period motor signs, ADLs, and
ON dyskinesia scores, although only the STN group had a sig-
nificant reduction in the doses of levodopa. These results were
sustained after 6 years of follow-up (61). A direct comparison of
both procedures was published in 2012 (39). This was a random-
ized, evaluator-blind study with 198 PD patients followed up for
at least 36 months, which concluded that the primary outcome,
OFF period motor improvement (including subscales for each
motor sign), was significantly improved, but the improvements
were similar, stable over time, and with parallel trends for both
targets. The scores for complications of levodopa therapy (UPDRS
IV), including dyskinesia, as well as the amount of ON period time
without troublesome LID were significantly improved for both
groups over 36 months, with non-significant, but greater decreases
in levodopa dosages in the STN group. Finally, one recent double-
blind study of 128 PD patients randomized for either form of
treatment, showed that patients who underwent STN DBS had
larger improvements in OFF period mean UPDRS motor score,
mean change in ADLs scores and mean reduction in medication
after surgery. OFF dystonia scores were similarly improved as well
as the time in ON phase without dyskinesia. The scores of the
dyskinesia rating scales were significantly better 12 months after
surgery for those who underwent GPi DBS. This difference proba-
bly occurred because the authors assessed patients after 12 months
with the same dose of levodopa used at baseline, however in daily
life, they may use lower doses, leading to less LID (40).
PRACTICAL ISSUES; SELECTION OF THE SURGICAL TARGET,
TECHNIQUE, AND PROGRAMING
Table 1 shows a summary of points that need to be considered
when indicating these DBS techniques.
Numerous studies have demonstrated the effectiveness of STN
DBS in controlling the appendicular motor signs of PD, how-
ever, this procedure is not considered to have as much of a direct
effect on the intensity of LID. The anti-dyskinetic effect of STN
DBS have been hypothesized to be related to allowing reduction
of dopaminergic drug dosages, with consequent improvement in
side effects, including LID. The persistence or worsening of LID
after STN DBS is common and is, in fact, indicative of the neces-
sity to reduce the dose of levodopa (62). Therefore, the si ne qua
non-condition for reduction of LID when STN DBS is considered,
is its capacity to enable a reduction of levodopa dosage. If, how-
ever, an adequate response of motor symptoms does not occur
post-operatively, dyskinesia will remain unchanged. Of impor-
tance, STN stimulation not uncommonly induces contralateral
dyskinesia, which may be persistent, and in some cases lead to the
implantation of rescue GPi leads.
On the other hand, GPi DBS seems to have a direct effect on the
reduction of dyskinesia. Patients undergoing this procedure typ-
ically cannot tolerate significantly lower doses of levodopa after
surgery, and still appreciate a marked reduction of dyskinesia.
Simplistically, patients who experience a good response of their
PD symptoms with levodopa, but whose primary and most sig-
nificant source of disability are dyskinesia may benefit from GPi
DBS (51). In other words, GPi DBS can be especially valuable for
cases in which LID are a dose-limiting factor for either maintain-
ing or introducing higher but necessary levels of dopaminergic
therapy. In addition, levodopa may have a synergistic effect on
GPi DBS, which is not seen after STN stimulation. Burchiel et al.,
for instance, in a randomized, double-blind study, comparing the
effects of STN and GPi DBS, showed that, in combination with
levodopa, UPDRS motor scores were significantly more improved
for patients who underwent the pallidal procedure. This combi-
nation was also more clinically significant for axial symptoms,
which are traditionally considered refractory to either form of
treatment alone (63). Another more recent meta-regression of
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long-term studies of cases who underwent these procedures con-
firmed that GPi DBS in combination with levodopa was correlated
with better scores for postural instability and gait disorder than
STN stimulation plus levodopa (64).
Selection of either target may also be influenced by the fact
that medications used for the treatment of PD are useful not
only for motor, but also for psychiatric, cognitive, sleep, and other
non-motor aspects of the disease, therefore, withdrawal or dose
reduction may not be a desired goal (65). Selection of the tar-
get should be based on the patient’s most disabling symptoms,
response, and side effects related to levodopa, and the ultimate
goals of therapy (66). If LID are a patient’s most disabling symp-
tom, especially if they require more immediate improvement due
to its severity and potential morbidity, then GPi DBS should
be considered with the knowledge that regardless of changes in
medication therapy after surgery there is a high likelihood that
dyskinesia will improve. On the other hand, patients undergoing
STN DBS must hope for a sufficiently good response after surgery
that will allow medications to be sufficiently reduced. If change in
parkinsonian motor symptoms after STN DBS are insufficient to
guarantee reduction of levodopa dosage, or if its reduction worsen
or induces non-motor symptoms, the intervention for dyskinesia
may be “unfruitful” (1).
In the case of a patient in whom, in addition to motor signs
of parkinsonism, medication side effects other than dyskinesia are
a primary source of disability (i.e., psychosis, behavioral changes,
etc.), STN DBS may be more desirable.
In general, when the presence of LID is the main problem and
indication for surgery, there are no formal differences in the pro-
cedures when compared to situations when the chief complaint
is another motor feature of the disease. However, a few minor
variables exist. Implantation of leads is typically performed while
patients are in the OFF condition to avoid disabling dyskinesia,
leading to motion artifacts during pre operative imaging and to
better microelectrode recording during the intraoperative proce-
dure (67). Other variations are used because of possible differential
anti-dyskinetic effects of stimulation at different sites within the
GPi as stimulation of two different sites within the nucleus induce
different effects on dyskinesia and response to dopaminergic treat-
ment. Studies have shown that stimulation of the most dorsal
aspects of the GPi in the OFF period usually leads to improvement
of the cardinal signs, especially bradykinesia, while inducing dysk-
inesia, mimicking the action of levodopa. When deeper (ventral)
sites within the nucleus were stimulated, signs worsened. In the
ON period, stimulation of the ventral GPi reduced dyskinesia but
may have worsened bradykinesia. Stimulation of the intermediate
area seems to provide a balance between these two extremes. It is
unclear whether these findings have a practical significance, but
their existence should be kept in mind during surgical planning,
positioning of the lead within the GPi, and during programing
sessions (56, 57).
Post-operative programing: GPi DBS
As a rule, the evaluation of stimulation-related beneficial effects is
typically less reliable during the first weeks after electrode implan-
tation, due to the lesion effect of the procedure. Therefore, the
initial programing should be performed after at least 2 weeks of
surgery. At this time, the patient should be in the OFF medication
condition, after 12 h of dopaminergic drug withdrawal. The first
step should focus on achieving the best improvement of the car-
dinal signs of parkinsonism. The second phase should address the
patient during the ON period, under the effect of levodopa, with
particular awareness for LID. Therefore, the goal of programing
should be attempting to achieve a good relief of PD symptoms in
the OFF condition, not associated with the occurrence of dyski-
nesia in the ON period, and with the highest threshold for side
effects of stimulation. This procedure should be performed for
all four contacts separately, defining a hierarchy for therapeutic
window (68).
In patients whose primary complaint is LID, an additional
programing session can be performed in a full ON condition to
confirm the adequate beneficial effect of stimulation, but is usu-
ally only indicated if there are difficulties suppressing dyskinesia.
Special attention must be directed to ensure that beneficial medica-
tion effects are not antagonized by stimulation, as well as the OFF
medication symptoms are not exacerbated, since different regions
within the GPi may have opposite effects on dyskinesia and on
the cardinal signs of parkinsonism, when stimulated. Fortunately,
the detrimental effects of stimulation on parkinsonism and the
response to levodopa have higher thresholds than the beneficial
effects on dyskinesia. As ventral GPi areas may provide good relief
of dyskinesia at the expense of loss of beneficial effect of levodopa,
a better stimulation response can be detected by using more cen-
tral contacts, which usually provide good relief of dyskinesia as
well as tremor, rigidity, and bradykinesia (56, 69). It is important
to point out that many experts have been unable to replicate the
differential effects of programing different contacts in the GPi, and
that in general the GPi has been found to be a much easier target
to optimize. The GPi target also allows for more flexibility that the
STN target, as was recently shown by Weaver et al. in VA study
36 months outcomes (39, 70).
Post-operative programing: STN DBS
As STN DBS ideally mimics the motor effects of levodopa in
many aspects, the main objective of initial programing in cases
of dyskinesia relies on providing a significant improvement of the
motor signs of parkinsonism and a concomitant decrease in lev-
odopa dosage, which, on average, reaches a 50% reduction (41).
Therefore, as in the case of GPi DBS, the first programing ses-
sion should preferentially be performed in patients during the
OFF period, holding all medications for PD for 12 h. In fact, most
experts that program STN and GPi DBS have patients report to
the clinic in an OFF medication condition, which provides a nearly
optimal programing scenario (no bias of medications). This is
generally enough for most patients, however some patients may
require longer OFF periods. In difficult cases, after programing for
reduction of bradykinesia, tremor, and, especially, rigidity, patients
should take their regular doses of levodopa and, in the ON state,
be assessed for adverse effects with the combination of stimula-
tion and medications, particularly dyskinesia. The patient should
be seen during this first session at the peak effect of levodopa,
and ideally should have access to expert programing for the next
few days, as dyskinesia may appear after a latency period of up
to several hours (71, 72). During the first few weeks and months
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after surgery, as stimulation is adjusted to provide the best relief of
parkinsonian symptoms, medication doses can be slowly titrated
downward, and LID tends to improve or resolve. Moreover, dysk-
inesia has been hypothesized to improve with chronic continuous
stimulation due to plastic changes as a direct effect of stimulation,
leading to desensitization of the neuronal circuitry underlying to
LID. Persistent dyskinesia is generally treated by further reduction
of medication (71).
In some instances, especially during the first few weeks after
DBS implantation, dyskinesia may be exacerbated and, in fact,
the induction of these involuntary movements in the short term
predicts a favorable long-term outcome (51). Thus, the particu-
lar electrode that induces dyskinesia is usually the most effective
contact for long-term therapy. In these cases, if reducing levodopa
leads to worsening of PD symptoms, medication doses should
be kept at the lowest adequate therapeutic level, and stimulation
amplitudes or other parameters should be reduced. Over time,
the threshold for induction of dyskinesia typically increases, and
amplitude can be gradually increased (73). Finally, if stimulation
using the most effective contact precipitates dyskinesia that can-
not be controlled except by unacceptable reduction of stimulation
intensity, programing the system to use a more proximal contact
in a monopolar configuration, or reprograming to a bipolar con-
figuration may be necessary. Addition of a contact dorsal to the
STN (perhaps in the zona incerta) may also provide better control
of dyskinesia (71).
CONCLUSION
Although STN and GPi procedures have different mechanisms
of action, both are effective treatments strategies to control LID.
GPi interventions may have a more immediate effect, independent
of reduction of levodopa daily dosage. On the other hand, sev-
eral centers tend to adopt STN DBS as this procedure also brings
marginally better improvements in OFF period motor scores than
GPI DBS, as indicated by a recent randomized controlled trial
(40). Overall, selection of the surgical target should be based
on each patient’s most disabling symptoms, medication response
and regimen, and goals of therapeutic intervention. Currently,
the literature is almost entirely focused on results that analyze
a combination of the best possible results in regards to global
improvements, therefore the ideal stimulation parameters specific
for the control of LID are unknown. Also, the anti-dyskinetic
effects of additional or combined targets, such as external and
internal pallidal stimulation, and the use of adaptive DBS remain
largely unexplored.
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